• MJHLS Brand Logo

© 2022 MJH Life Sciences™ and Managed Healthcare Executive. All rights reserved.

Expert hematologist/oncologist David R. Gandara, MD, highlights the value comprehensive genomic profiling has in guiding therapeutic decisions.

EP. 1: Comprehensive Genomic Profiling: Advancing Cancer Care

December 10th 2021

A clinical expert shared insight on the evolution of comprehensive genomic profiling and how it has impacted cancer care.

EP. 2: Comprehensive Genomic Profiling: Tissue-Based + ctDNA Testing

December 23rd 2021

David Gandara, MD, focuses on the differences between liquid biopsy and tissue-based CGP, suggesting a role for both in the current treatment landscape.

EP. 3: The Clinical Value of Comprehensive Genomic Profiling

December 23rd 2021

Expert perspective on clinical and personal improvements in cancer care made available by appropriate use of comprehensive genomic profiling.

EP. 4: The Economic Value of Comprehensive Genomic Profiling

January 5th 2022

A review of how comprehensive genomic profiling can better inform treatment planning and alleviate health care economic burden.

EP. 5: Is There an Ideal Patient for Comprehensive Genomic Profiling?

January 5th 2022

David Gandara, MD, explains how the scope of comprehensive genomic profiling has shifted from a select few patients to the majority.

EP. 6: Benefits of Commercially Available CGP Tests

January 12th 2022

A brief discussion on the value of commercially available comprehensive genomic profiling over homegrown testing.

EP. 7: Supporting Access to Comprehensive Genomic Profiling

January 12th 2022

Considering the value of comprehensive genomic profiling, David Gandara, MD, highlights the importance of supporting access to testing.

EP. 8: Expanding the Use of CGP in Screening and Surgery

January 17th 2022

Closing out his discussion on CGP, David Gandara, MD, looks toward future opportunities for CGP in screening patients before or after surgery.